Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro [0.03%]
不同腹膜癌细胞系对HIPEC和PIPAC的化学敏感性：体外实验对比双药与标准药物方案
Jürgen Weinreich,Florian Struller,Iaroslav Sautkin et al.
Jürgen Weinreich et al.
We performed an in-vitro study testing the chemosensitivity of peritoneal cancer cell lines (SW620, HCT116, MKN45, 23,132/87, OAW42) to various cytostatic drug regimens. A duplex drug, characterized by reversible linking of the antimetaboli...
Comparative Study
Investigational new drugs. 2019 Jun;37(3):415-423. DOI:10.1007/s10637-018-0641-6 2019
Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitors [0.03%]
设计、合成及生物评估新型硫胺-1,2,3-三氮唑衍生物作为微管聚合抑制剂抗增殖作用
Shewei Guo,Yingwei Zhen,Mengguo Guo et al.
Shewei Guo et al.
Microtubule as an important target in the cancer therapy was used to design novel tubulin polymerization inhibitors. Sulfanilamide-1,2,3-triazole hybrids were designed by a molecular hybridization strategy and their antiproliferative activi...
Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial [0.03%]
卡培他滨联合厄洛替尼和贝伐单抗治疗胰腺癌的Ⅱb期临床研究(REBECA)
Christian Dittrich,Robert Königsberg,Martina Mittlböck et al.
Christian Dittrich et al.
Background Purpose of this phase Ib trial was to establish the maximum tolerable dose (MTD) of capecitabine and to escalate the dosages of erlotinib and bevacizumab to determine the recommended phase II dose (RP2D) in patients with advanced...
Clinical Trial
Investigational new drugs. 2019 Feb;37(1):127-138. DOI:10.1007/s10637-018-0639-0 2019
The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines [0.03%]
海洋天然产物Scalarin通过抑制PANC-1和MIA PaCa-2胰腺癌细胞系中受体foradvanced糖基化终末产物(RAGE)和自噬发挥作用
Esther Amalia Guzmán,Tara Peterson Pitts,Maria Cristina Diaz et al.
Esther Amalia Guzmán et al.
Pancreatic cancer, the fourth leading cause of cancer death in the United States, has a negative prognosis because metastasis occurs before symptoms manifest. Although combination therapies are showing improvements in treatment, the surviva...
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer [0.03%]
用于胆道癌和胰腺癌患者的雷西木斯联合S-1的I期临床研究
Masafumi Ikeda,Izumi Ohno,Hideki Ueno et al.
Masafumi Ikeda et al.
Resminostat is an oral hydroxamate inhibitor of class I, IIb, and IV histone deacetylases. S-1 is widely used to treat biliary tract cancer and pancreatic cancer in Japan. We performed a phase I study of resminostat combined with S-1 as sec...
Clinical Trial
Investigational new drugs. 2019 Feb;37(1):109-117. DOI:10.1007/s10637-018-0634-5 2019
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma [0.03%]
关于Galunisertib联合索拉非尼治疗不可切除的肝细胞癌患者的Ib期临床研究
Masafumi Ikeda,Manabu Morimoto,Masaomi Tajimi et al.
Masafumi Ikeda et al.
Background Galunisertib inhibits type I transforming growth factor-beta receptor serine/threonine kinase. The primary objective of this study was to evaluate the safety and tolerability of galunisertib in combination with sorafenib in Japan...
Clinical Trial
Investigational new drugs. 2019 Feb;37(1):118-126. DOI:10.1007/s10637-018-0636-3 2019
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors [0.03%]
一项I期first-in-human研究：AMG 900（一种口服多靶点aurora激酶抑制剂）在晚期实体瘤成年患者中的作用
Michael Carducci,Montaser Shaheen,Ben Markman et al.
Michael Carducci et al.
Background Aurora kinase overexpression or amplifications are associated with high proliferation, poor prognosis, and therapeutic resistance in human tumors. AMG 900 is an investigational, oral, selective pan-Aurora kinase inhibitor. Method...
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein [0.03%]
用于治疗EML4-Alk融合蛋白型非小细胞肺癌的艾乐替尼长期间疗程后出现脑膜复发
Takahisa Kawamura,Haruyasu Murakami,Haruki Kobayashi et al.
Takahisa Kawamura et al.
The recent approval of anaplastic lymphoma kinase (ALK) inhibitors for the treatment of ALK-rearranged non-small cell lung cancer (NSCLC) has dramatically transformed cancer therapy. However, leptomeningeal metastases (LM) are frequent and ...
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world [0.03%]
老年或经治晚期非小细胞肺癌患者的口服最小化剂量长春瑞滨治疗（OMV）：真实世界的疗效及药代动力学研究
Felice Pasini,Carmen Barile,Donatella Caruso et al.
Felice Pasini et al.
Background Oral metronomic therapy (OMV) is particularly suitable for palliative care, and schedules adapted for unfit patients are advisable. This study investigated the effects of oral vinorelbine given every other day without interruptio...
Clinical Trial
Investigational new drugs. 2018 Oct;36(5):927-932. DOI:10.1007/s10637-018-0631-8 2018
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints [0.03%]
卡博替尼诱导的血清肌酸激酶升高和肌肉骨骼症状投诉
Sarah E Stump,Young E Whang,Daniel J Crona
Sarah E Stump
Cabozantinib is a multikinase inhibitor approved for the treatment of metastatic medullary thyroid cancer and advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. While associations between serum ...